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Abstract
Patients with cancer have a high risk of developing cancer-associated thrombosis (CAT). Current guidelines suggest 
preferential use of low molecular weight heparins (LMWH) in CAT. The real-world data show that compliance with 
recommended LMWH therapy in cancer patients is low. Many patients discontinue injectable anticoagulants 
prematurely, in some cases even after a month, despite a high recurrence rate in this population. In recent 
years an increasing number of cancer patients are treated with direct oral anticoagulants, mainly rivaroxaban. 
Recent data confirming the safety and efficacy of rivaroxaban are starting to emerge and support the growing 
trend of using direct oral anticoagulants in cancer patients. If positive results of the recently completed SELECT-D 
trial are confirmed in the upcoming trials and registries of CALLISTO project, the guidelines for the treatment 
of CAT will have to be revised in favour of DOAC use in cancer-associated thrombosis. 
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Introduction
Cancer-associated thrombosis is a complex problem 
in oncological patients who have significantly higher risk 
of developing venous thromboembolism (VTE) when 
compared with the general population [1, 2], the risk 
is estimated to be up to 7 times higher than in patients 
without cancer [3–6]. Between 4 and 20% of them 
will be affected with CAT [7–9], as the cancer itself is 
a hypercoagulable state [10, 11]. Additionally, reduced 
mobility, dehydration, cachexia are frequent in this 
population. Other factors facilitating thrombosis include 
chemotherapy agents, indwelling venous catheters and 
surgical procedures. Chemotherapy leads to a 2–6 fold 
increase in the likelihood of VTE compared with the 
risk in the general population [3, 12]. VTE is the second 
leading cause of death in this population [7, 13] and has 
a significant impact on morbidity and mortality [14]. 
According to the 2016 edition of the American 
College of Chest Physicians (ACCP) guidelines, the pre-
ferred antithrombotic agents are low-molecular-weight 
heparins (LMWH) [15]. In practice, many patients with 
VTE and cancer either do not receive this treatment 
or it is too short or they are treated with VKA instead. 
The duration of treatment with LMWH should last 
3 to 6 months and is recommended both by general 
[15] and oncology guidelines [14, 16], it should be ex-
tended beyond 6 months in patients with cancer and 
a high risk of recurrence, inoperable malignancy and 
low bleeding risk. 
Venous thromboembolism  
in cancer patients
The risk of VTE is the highest in the first months 
after diagnosis, but the risk of recurrence afterwards 
is never negligible and reaches the peak within the first 
6–12 months [17]. The treatment of CAT is associated 
with a 3-fold higher rate of recurrent thrombosis than 
99www.journals.viamedica.pl/acta_angiologica
 Grzegorz Halena, Agnieszka Kulik, Current evidence of rivaroxaban in cancer-associated thrombosis
in non-cancer patients [2, 18–22]. While antithrombotic 
treatment is an imperative in CAT, anticoagulant-in-
duced bleeding risk should be always kept in mind, as 
it is increased in this population by 2.5 to 6 fold [2, 11]. 
A similar pattern has been observed with rivaroxaban [23].
VTE is one of the leading causes of death in this 
population, and negatively impacts treatment outcome 
[24–28]. The survival in cancer patients and diagnosed 
with VTE is lower (up to three times) when compared 
with cancer patients with no thrombosis [8, 29]. The 
highest rates of VTE are seen in patients with cancer 
of the brain, pancreas (especially metastatic), stomach, 
kidney, bladder, uterus, lung, or ovary [8, 9, 30, 31] 
and it is very likely to occur during the first year of the 
follow-up.
A recent meta-analysis reported on the incidence 
rates of venous thrombosis in cancer patients, stratified 
by background risk of venous thrombosis. They con-
stitute an inhomogeneous group with the of the risk of 
developing VTE varying from 13 per 1000 person-years 
to 68 in high-risk patients (metastatic and high-grade 
cancer) [4]. 
Treatment of venous thromboembolism 
in cancer patients
Warfarin in no longer the standard of care in CAT 
due to its multiple interactions with other drugs, 
unpredictable INR and impaired oral drug intake due 
to vomiting, mucositis, and diarrhoea that often ac-
company cancer. VKA treatment in cancer patients is 
characterised with higher rates of major bleeding and 
recurrence in comparison with heparin [32, 33]. The 
VKA therapy is often suboptimal, even selected and 
closely monitored patients in pivotal trials had unther-
apeutic INR time (47% in CATCH and 46% in CLOT 
trial respectively).
The CLOT trial was the largest study favouring 
the use of dalteparin over warfarin in CAT [34]. It has 
shown the superiority of dalteparin in comparison to 
warfarin in preventing VTE recurrence and LMWHs 
have become standard of care for cancer-associated 
thrombosis. Ten years later, similar CATCH trial, which 
enrolled 900 patients, and compared tinzaparin to 
warfarin, failed to demonstrate a significant reduction 
of recurrent VTE for patients treated with LMWH for 
CAT (7.2% recurrent VTE for tinzaparin vs. 10.5% for 
warfarin). There were no differences in major bleeding 
between the arms of the study [35].
Both Einstein trials demonstrated noninferiority of 
rivaroxaban compared to standard therapy in general 
population [36, 37]. In consequence, this new standard 
has been endorsed by 2016 ACCP guidelines. The re-
sults of CAT treatment from both EINSTEIN-DVT and 
EINSTEIN PE studies signalled favourable treatment 
results in this subgroup of patients [38]. Recurrent VTE 
occurred in 7% of patients treated with LMWH and vi-
tamin K antagonists (VKA) and in 5% of patients treated 
with rivaroxaban, while clinically relevant bleeding was 
observed in 14% of patients in the rivaroxaban arm and 
in 16% of patients receiving LMWH/VKA. Major bleed-
ing occurred in 2% of patients on rivaroxaban and in 
5% of patients LMWH/VKA. Patients with active cancer 
constituted only 5% of the studied population (6% in 
EINSTEIN-DVT and 4.6% in EINSTEIN PE), therefore 
the results could not be generalised. The details of 
malignancies in EINSTEIN trials were not collected, 
which has limited the adoption of rivaroxaban in clinical 
practice in cancer patients, also the subset of patients 
with cancer was too small to extrapolate the results 
of both studies to the population of cancer patients. 
According to the 2016 ACCP guidelines, LMWHs 
are the preferred treatment for CAT. The efficacy and 
positive safety profile of rivaroxaban in CAT led to further 
studies (head-to-head comparison of LMWH vs. rivarox-
aban in CAT) which will be discussed later in the article.
Overview of VTE treatment in cancer 
according to clinical guidelines
Specific national and international guidelines for VTE 
treatment in CAT were published or updated by a num-
ber of societies in recent years. American College of 
Chest Physicians, the American Society of Clinical On-
cology, the National Comprehensive Cancer Network 
and other societies updated their guidelines in the man-
agement of CAT between 2015 and 2016 [14, 15, 39]. 
Due to the lack of data from the cancer-specific 
randomised trials, LMWHs are recommended as the 
first-line treatment for CAT, both in the acute phase 
and in long-term treatment. Oral anticoagulants were 
reserved for patients unable or unwilling to use long-
term parenteral therapy. ACCP recognises DOACs as 
an alternative for LMWH based on grade 2C evidence 
(the same as for VKA). With regard to VTE prevention 
in ambulatory cancer patients, thromboprophylaxis 
is not recommended or there are no specific recom-
mendations. In March of 2018 new guidelines from the 
International Society of Thrombosis and Hemostasis 
have been issued, based on 2 available RCTs in CAT 
population (Hokusai Cancer and Select-D). It has been 
highlighted that only rivaroxaban and edoxaban have 
been subjected to randomised trials in CAT population. 
It has been suggested that those two drugs should be 
preferentially used in cancer patients when the risk 
of bleeding is low, in those where the bleeding is high 
(gastroesophageal cancer, gastritis, mucositis) LMWH 
are still the best choice [40]. 
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Are current guidelines implemented? 
Prescription patterns versus guidelines
Due to poor compliance with LMWHs, a growing 
number of cancer patients are receiving rivaroxaban for 
the treatment of CAT. Among 1.7 million US patients 
diagnosed with cancer and treated for CAT between 
2009 and 2014, warfarin was prescribed in the 50% of 
patients despite recommendations, 40% were treated 
with LMWH and only 10% with other drugs [41]. In 
2014 half of them were treated with LMWH, warfarin 
use fell below 30% and rivaroxaban use increased 
to 20%. Less than 1% of patients were treated with 
apixaban or dabigatran. The percentage of patients on 
rivaroxaban increased in the final year of the study, 
surpassing warfarin [41]. 
Compliance for LMWH was low, as many as 44% 
of patients discontinued therapy in less than a month, 
including patients with advanced cancer [42]. After 
6 months only 13% of patients remained on LMWH. 
The data reflect patients’ dissatisfaction with injectable 
anticoagulants and preference for oral drugs of which 
warfarin is nowadays less often prescribed in favour of 
rivaroxaban. The prescription patterns among patients 
in the US reflect poor implementation of the recent 
guidelines and preference for oral anticoagulants versus 
injectable anticoagulants in cancer patients. 
Direct oral anticoagulants for  
cancer-associated thrombosis
 All recent pivotal trials with rivaroxaban (Einstein) , 
apixaban (AMPLIFY) and edoxaban (Hokusai) included 
small samples of cancer patients [36, 37, 43, 44]. None 
of those trials targeted specifically cancer population. 
The indirect comparison of direct oral anticoagulants 
(DOAC) efficacy and safety of versus VKA in patients 
with CAT was assessed in a recent meta-analysis in-
cluding 19 060 patients [45]. The publication revealed 
similar efficacy and a non-significant relative risk favour-
ing improved safety with DOACs. Other data confirm 
that DOACs can be as effective and safe as traditional 
LMWH/VKA combination [46], the data are supported 
by other publications, it has also been found that VKA 
is responsible for more bleeding events than LMWH 
[47, 48]. Another meta-analysis evaluating 3242 patients 
found that recurrence rate and bleeding rates were 
comparable between DOACs and LMWH [49]. This 
finding has been confirmed by other retrospective, 
single-centre studies [23, 50].
A retrospective cohort study from the US cov-
ering the period between 2007 and 2015 found that 
the median duration of therapy with LMWH was only 
1 month versus 3 months and 3.5 months for rivaroxaban 
and warfarin respectively. Risk of bleeding was similar 
between three agents, but the recurrence of VTE was 
the lowest for rivaroxaban [51]. Randomised controlled 
trials data comparing rivaroxaban with LMWH for long-
term treatment are starting to emerge. Select-D is one 
of nine studies planned as a part of a bigger CALLISTO 
project, which will examine the use of rivaroxaban in 
people with active cancer. The goal of the project is to 
accumulate and analyse data of 4000 patients, both in 
randomised trials and registries. 
The programme will research not only treatment 
but also prevention of VTE and additionally patient 
preference with regard to different anticoagulation 
regimens used for VTE treatment.
The ongoing CONCO-011 trial will report both the 
traditional endpoints (safety and efficacy) and also the 
satisfaction of patients treated with rivaroxaban versus 
LMWH. The trial is expected to be completed in 2018. 
Select-D randomised trial
Select-D was the first prospective randomised trial 
comparing the efficacy and safety of rivaroxaban versus 
dalteparin in cancer patients presenting with the first 
symptomatic VTE including PE. Patients from 58 cen-
tres in Great Britain were followed between 2013 and 
2016, the study randomised 406 patients (203 in each 
arm). Patients presented with locally advanced disease 
(38%), metastatic disease (59%), or haematological 
malignancies (3%). Recurrent VTE occurred in 4% 
(95% CI 2–9%) in the rivaroxaban group and 11% 
(95% CI 7–17%) in the dalteparin group. There were 
no differences between major bleeding in groups (both 
at 3–4%), clinically relevant bleeding was significantly 
higher with rivaroxaban (17%; 95% CI 12–22%) than 
with dalteparin (5%; 95% CI 3–9%). There were no 
intracranial bleedings. The authors concluded, that 
rivaroxaban is characterised by a very low VTE recur-
rence rate at 6 months in CAT, with a similar number 
of major bleeds reported across both trial arms, but 
more clinically relevant non-major bleeds [52].
CONCLUSIONS
There is an unmet need for anticoagulation therapy 
with an acceptable benefit-risk profile, offering therapy 
that patients with cancer are willing to comply with, 
both in the acute and in the long-term phase of VTE 
treatment. 
The current evidence for DOACs in patients with 
CAT is favourable. Despite the lack of updated recom-
mendations, increasing numbers of patients are treated 
with rivaroxaban for CAT, because too many of them 
do not comply with prescribed LMWH therapy. Lack 
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of long-term acceptance for injectable anticoagulants 
must be taken into account when initiating therapy in 
such patients. More data are needed with regard to the 
type of cancer and its stage versus DOACs efficacy and 
safety in upcoming trials. Oral anticoagulants may play 
a limited role in patients with gastrointestinal bleeding, 
active gastrointestinal malignancy, nausea and vomiting. 
LMWHs still will be preferred and will be more pre-
dictable in those patients. 
Incidences of recurrent VTE and major bleeding 
among rivaroxaban-treated CAT patients seen in me-
ta-analysis of real-world studies are similar to those 
seen with DOACs (rivaroxaban and edoxaban) in re-
cently published randomised clinical trials for general 
population. However, the pooled incidence of all-cause 
mortality in this analysis was lower than seen in CAT 
trials, suggesting that rivaroxaban may preferentially 
be prescribed by clinicians to CAT patients with less 
severe cancer. With many trials underway, the paradigm 
of treating CAT preferentially with LMWH will be 
challenged soon. There is probably no class effect for 
DOACs, therefore each new drug has to be studied sep-
arately and results from one study with a specific DOAC 
cannot be extrapolated to another oral anticoagulant. 
Lack of recognition of DOAC for cancer patients is a 
reflection of data paucity from cancer-specific trials in 
2015 and 2016 when many guidelines were updated. In 
2018 we can demonstrate data proving that rivaroxaban 
can be offered as an alternative to selected cancer, or 
even the first choice therapy in patients unwilling to take 
injectable anticoagulants. Finally, it is worth mentioning 
that rivaroxaban in the only DOAC available in Poland 
where the summary of product characteristics does not 
forbid its use in cancer patients.
Conflict of interest
None.
References
1. Wells PS, Forgie MA, Rodger MA. Treatment of venous throm-
boembolism. JAMA. 2014; 311(7): 717–728, doi: 10.1001/ 
/jama.2014.65, indexed in Pubmed: 24549552.
2. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent ve-
nous thromboembolism and bleeding complications during 
anticoagulant treatment in patients with cancer and venous 
thrombosis. Blood. 2002; 100(10): 3484–3488, doi: 10.1182/ 
/blood-2002-01-0108, indexed in Pubmed: 12393647.
3. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep 
vein thrombosis and pulmonary embolism: a population-based 
case-control study. Arch Intern Med. 2000; 160(6): 809–815, 
indexed in Pubmed: 10737280.
4. Walker AJ, Card TR, West J, et al. Incidence of venous throm-
boembolism in patients with cancer - a cohort study using 
linked United Kingdom databases. Eur J Cancer. 2013; 49(6): 
1404–1413, doi: 10.1016/j.ejca.2012.10.021, indexed in Pu-
bmed: 23146958.
5. Cronin-Fenton DP, Søndergaard F, Pedersen LA, et al. Hos-
pitalisation for venous thromboembolism in cancer patients 
and the general population: a population-based cohort study in 
Denmark, 1997-2006. Br J Cancer. 2010; 103(7): 947–953, doi: 
10.1038/sj.bjc.6605883, indexed in Pubmed: 20842120.
6. Blom JW, Doggen CJM, Osanto S, et al. Malignancies, prothrom-
botic mutations, and the risk of venous thrombosis. JAMA. 
2005; 293(6): 715–722, doi: 10.1001/jama.293.6.715, indexed 
in Pubmed: 15701913.
7. Lyman GH. Venous thromboembolism in the patient with 
cancer: focus on burden of disease and benefits of thrombo-
prophylaxis. Cancer. 2011; 117(7): 1334–1349, doi: 10.1002/ 
/cncr.25714, indexed in Pubmed: 21425133.
8. Chew HK, Wun T, Harvey D, et al. Incidence of venous throm-
boembolism and its effect on survival among patients with com-
mon cancers. Arch Intern Med. 2006; 166(4): 458–464, doi: 
10.1001/archinte.166.4.458, indexed in Pubmed: 16505267.
9. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with 
solid tumors: determination of frequency and characteristics. 
Thromb Haemost. 2002; 87(4): 575–579, indexed in Pubmed: 
12008937.
10. Dipasco PJ, Misra S, Koniaris LG, et al. The thrombophilic state 
in cancer part II: cancer outcomes, occult malignancy, and can-
cer suppression. J Surg Oncol. 2012; 106(4): 517–523, doi: 
10.1002/jso.23085, indexed in Pubmed: 22487896.
11. Schulman S. Treatment of venous thromboembolism with new 
oral anticoagulants according to patient risk. Semin Thromb 
Hemost. 2015; 41(2): 160–165, doi: 10.1055/s-0035-1544157, 
indexed in Pubmed: 25682084.
12. Blom JW, Vanderschoot JPM, Oostindiër MJ, et al. Incidence of 
venous thrombosis in a large cohort of 66,329 cancer patients: 
results of a record linkage study. J Thromb Haemost. 2006; 4(3): 
529–535, doi: 10.1111/j.1538-7836.2006.01804.x, indexed in 
Pubmed: 16460435.
13. Khorana AA. Venous thromboembolism and prognosis in cancer. 
Thromb Res. 2010; 125(6): 490–493, doi: 10.1016/j.throm-
res.2009.12.023, indexed in Pubmed: 20097409.
14. Lyman GH, Bohlke K, Khorana AA, et al. American Society of 
Clinical Oncology. Venous thromboembolism prophylaxis and 
treatment in patients with cancer: American Society of Clini-
cal Oncology clinical practice guideline update 2014. J Oncol 
Pract. 2015; 11(3): e442–e444, doi: 10.1200/JOP.2015.004473, 
indexed in Pubmed: 25873061.
15. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for 
VTE disease: CHEST guideline and expert panel report. Chest. 
2016; 149(2): 315–352, doi: 10.1016/j.chest.2015.11.026, in-
dexed in Pubmed: 26867832.
16. Farge D, Bounameaux H, Brenner B, et al. International clinical 
practice guidelines including guidance for direct oral anticoag-
ulants in the treatment and prophylaxis of venous thrombo-
embolism in patients with cancer. Lancet Oncol. 2016; 17(10): 
e452–e466, doi: 10.1016/S1470-2045(16)30369-2, indexed in 
Pubmed: 27733271.
17. Heit JA, Spencer FA, White RH. The epidemiology of venous 
thromboembolism. J Thromb Thrombolysis. 2016; 41(1): 
3–14, doi: 10.1007/s11239-015-1311-6, indexed in Pubmed: 
26780736.
102
Acta Angiol, 2018, Vol. 24, No. 3
www.journals.viamedica.pl/acta_angiologica
18. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thrombo-
embolism after deep vein thrombosis: incidence and risk factors. 
Arch Intern Med. 2000; 160(6): 769–774, indexed in Pubmed: 
10737276.
19. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recur-
rence after deep vein thrombosis and pulmonary embolism: 
a population-based cohort study. Arch Intern Med. 2000; 160(6): 
761–768, indexed in Pubmed: 10737275.
20. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical 
course of acute deep venous thrombosis. Ann Intern Med. 1996; 
125(1): 1–7, indexed in Pubmed: 8644983.
21. Trujillo-Santos J, Nieto JA, Tiberio G, et al. RIETE Registry. Pre-
dicting recurrences or major bleeding in cancer patients with 
venous thromboembolism. Findings from the RIETE Registry. 
Thromb Haemost. 2008; 100(3): 435–439, indexed in Pubmed: 
18766259.
22. Falanga A, Zacharski L. Deep vein thrombosis in cancer: the 
scale of the problem and approaches to management. Ann 
Oncol. 2005; 16(5): 696–701, doi: 10.1093/annonc/mdi165, in-
dexed in Pubmed: 15802275.
23. Bott-Kitslaar DM, Saadiq RA, McBane RD, et al. Efficacy and 
safety of rivaroxaban in patients with venous thromboembolism 
and active malignancy: a single-center registry. Am J Med. 2016; 
129(6): 615–619, doi: 10.1016/j.amjmed.2015.12.025, indexed 
in Pubmed: 26797081.
24. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism 
is a leading cause of death in cancer patients receiving outpa-
tient chemotherapy. J Thromb Haemost. 2007; 5(3): 632–634, 
doi: 10.1111/j.1538-7836.2007.02374.x, indexed in Pubmed: 
17319909.
25. Anderson LA, Moore SC, Gridley G, et al. Concomitant and 
antecedent deep venous thrombosis and cancer survival in 
male US veterans. Leuk Lymphoma. 2011; 52(5): 764–770, 
doi: 10.3109/10428194.2010.551572, indexed in Pubmed: 
21271864.
26. Chen W, Zhang Y, Yang Y, et al. Prognostic significance of arterial 
and venous thrombosis in resected specimens for non-small cell 
lung cancer. Thromb Res. 2015; 136(2): 451–455, doi: 10.1016/j.
thromres.2015.06.014, indexed in Pubmed: 26099644.
27. Diaz ES, Walts AE, Karlan BY, et al. Venous thromboembo-
lism during primary treatment of ovarian clear cell carcinoma 
is associated with decreased survival. Gynecol Oncol. 2013; 
131(3): 541–545, doi: 10.1016/j.ygyno.2013.09.005, indexed in 
Pubmed: 24041880.
28. Hicks LK, Cheung MC, Ding K, et al. Venous thromboembolism 
and nonsmall cell lung cancer: a pooled analysis of National 
Cancer Institute of Canada Clinical Trials Group trials. Cancer. 
2009; 115(23): 5516–5525, doi: 10.1002/cncr.24596, indexed in 
Pubmed: 19711465.
29. Sørensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers 
associated with venous thromboembolism. N Engl J Med. 2000; 
343(25): 1846–1850, doi: 10.1056/NEJM200012213432504, in-
dexed in Pubmed: 11117976.
30. Stein PD, Beemath A, Meyers FA, et al. Incidence of venous 
thromboembolism in patients hospitalized with cancer. Am J 
Med. 2006; 119(1): 60–68, doi: 10.1016/j.amjmed.2005.06.058, 
indexed in Pubmed: 16431186.
31. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recur-
rent thromboembolic disease among patients with malignancy 
versus those without malignancy. Risk analysis using Medicare 
claims data. Medicine (Baltimore). 1999; 78(5): 285–291, in-
dexed in Pubmed: 10499070.
32. Farge D, Bounameaux H, Brenner B, et al. International clinical 
practice guidelines for the treatment and prophylaxis of venous 
thromboembolism in patients with cancer. J Thromb Haemost. 
2013; 11(1): 56–70, doi: 10.1111/jth.12070, indexed in Pubmed: 
23217107.
33. Lee AYY, Peterson EA, Wu C, et al. Treatment of cancer-associat-
ed thrombosis. Blood. 2013; 122(14): 2310–2317, doi: 10.1182/ 
/blood-2013-04-460162, indexed in Pubmed: 23843493.
34. Lee AYY, Levine MN, Baker RI, et al. Randomized Comparison 
of Low-Molecular-Weight Heparin versus Oral Anticoagulant 
Therapy for the Prevention of Recurrent Venous Thromboem-
bolism in Patients with Cancer (CLOT) Investigators. Low-mo-
lecular-weight heparin versus a coumarin for the prevention 
of recurrent venous thromboembolism in patients with can-
cer. N Engl J Med. 2003; 349(2): 146–153, doi: 10.1056/NEJ-
Moa025313, indexed in Pubmed: 12853587.
35. Agnes YY, Lee RB, Janas MS, et al. A randomized trial of long-
term tinzaparin, a low molecular weight heparin (LMWH), ver-
sus warfarin for treatment of acute venous thromboembolism 
(VTE) in cancer patients — the CATCH Study. Cancer-Associated 
Thrombosis. 2013: 231–242, doi: 10.3109/9781420048001-17.
36. Bauersachs R, Berkowitz SD, Brenner B, et al. EINSTEIN Inves-
tigators. Oral rivaroxaban for symptomatic venous thromboem-
bolism. N Engl J Med. 2010; 363(26): 2499–2510, doi: 10.1056/
NEJMoa1007903, indexed in Pubmed: 21128814.
37. Büller HR, Prins MH, Lensin AWA, et al. EINSTEIN–PE 
Investigators. Oral rivaroxaban for the treatment of symp-
tomatic pulmonary embolism. N Engl J Med. 2012; 366(14): 
1287–1297, doi: 10.1056/NEJMoa1113572, indexed in Pubmed: 
22449293.
38. Prins MH, Lensing AWa, Bauersachs R, et al. EINSTEIN In-
vestigators. Oral rivaroxaban versus standard therapy for the 
treatment of symptomatic venous thromboembolism: a pooled 
analysis of the EINSTEIN-DVT and PE randomized studies. 
Thromb J. 2013; 11(1): 21, doi: 10.1186/1477-9560-11-21, in-
dexed in Pubmed: 24053656.
39. Streiff MB, Holmstrom B, Ashrani A, et al. Cancer-Associated 
Venous Thromboembolic Disease, Version 1.2015. J Natl Com-
pr Canc Netw. 2015; 13(9): 1079–1095, indexed in Pubmed: 
26358792.
40. Khorana AA, Noble S, Lee AYY, et al. Role of direct oral antico-
agulants in the treatment of cancer-associated venous thrombo-
embolism: guidance from the SSC of the ISTH. J Thromb Hae-
most. 2018; 16(9): 1891–1894, doi: 10.1111/jth.14219, indexed 
in Pubmed: 30027649.
41. Khorana AA, Yannicelli D, McCrae KR, et al. Evaluation of US 
prescription patterns: Are treatment guidelines for cancer-as-
sociated venous thromboembolism being followed? Thromb 
Res. 2016; 145: 51–53, doi: 10.1016/j.thromres.2016.07.013, 
indexed in Pubmed: 27485998.
42. Qureshi W, Ali Z, Amjad W, et al. Venous Thromboembolism 
in Cancer: An Update of Treatment and Prevention in the Era 
of Newer Anticoagulants. Front Cardiovasc Med. 2016; 3: 24, 
doi: 10.3389/fcvm.2016.00024, indexed in Pubmed: 27517038.
43. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY Investigators. 
Oral apixaban for the treatment of acute venous thromboem-
103www.journals.viamedica.pl/acta_angiologica
 Grzegorz Halena, Agnieszka Kulik, Current evidence of rivaroxaban in cancer-associated thrombosis
bolism. N Engl J Med. 2013; 369(9): 799–808, doi: 10.1056/ 
/NEJMoa1302507, indexed in Pubmed: 23808982.
44. Büller HR, Décousus H, Grosso MA, et al. Hokusai-VTE Investi-
gators. Edoxaban versus warfarin for the treatment of sympto-
matic venous thromboembolism. N Engl J Med. 2013; 369(15): 
1406–1415, doi: 10.1056/NEJMoa1306638, indexed in Pubmed: 
23991658.
45. van der Hulle T, den Exter PL, Kooiman J, et al. Meta-analysis of 
the efficacy and safety of new oral anticoagulants in patients with 
cancer-associated acute venous thromboembolism. J Thromb 
Haemost. 2014; 12(7): 1116–1120, doi: 10.1111/jth.12605, in-
dexed in Pubmed: 24819040.
46. Vedovati MC, Germini F, Agnelli G, et al. Direct oral antico-
agulants in patients with VTE and cancer: a systematic review 
and meta-analysis. Chest. 2015; 147(2): 475–483, doi: 10.1378/
chest.14-0402, indexed in Pubmed: 25211264.
47. Brunetti ND, Gesuete E, De Gennaro L, et al. Direct oral an-
ti-coagulants compared with vitamin-K inhibitors and low-mo-
lecular-weight-heparin for the prevention of venous thrombo-
embolism in patients with cancer: A meta-analysis study. Int J 
Cardiol. 2017; 230: 214–221, doi: 10.1016/j.ijcard.2016.12.168, 
indexed in Pubmed: 28062137.
48. Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of 
anticoagulant therapy for the treatment of acute cancer-as-
sociated thrombosis: a systematic review and meta-analysis. 
Thromb Res. 2014; 134(6): 1214–1219, doi: 10.1016/j.throm-
res.2014.09.039, indexed in Pubmed: 25457583.
49. Posch F, Königsbrügge O, Zielinski C, et al. Treatment of ve-
nous thromboembolism in patients with cancer: A network 
meta-analysis comparing efficacy and safety of anticoagulants. 
Thromb Res. 2015; 136(3): 582–589, doi: 10.1016/j.throm-
res.2015.07.011, indexed in Pubmed: 26210891.
50. Mantha S, Laube E, Miao Y, et al. Safe and effective use of rivar-
oxaban for treatment of cancer-associated venous thromboem-
bolic disease: a prospective cohort study. J Thromb Thrombol-
ysis. 2017; 43(2): 166–171, doi: 10.1007/s11239-016-1429-1, 
indexed in Pubmed: 27696084.
51. Streiff MB, Milentijevic D, McCrae K, et al. Effectiveness and 
safety of anticoagulants for the treatment of venous throm-
boembolism in patients with cancer. Am J Hematol. 2018; 
93(5): 664–671, doi: 10.1002/ajh.25059, indexed in Pubmed: 
29396864.
52. Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral 
Factor Xa Inhibitor With Low Molecular Weight Heparin in 
Patients With Cancer With Venous Thromboembolism: Results 
of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20): 
2017–2023, doi: 10.1200/JCO.2018.78.8034, indexed in Pu-
bmed: 29746227.
